阿托伐他汀对急性冠脉综合征患者外周血炎性因子的影响

目的探讨急性冠脉综合征（ACS）患者外周血单个核细胞环氧化酶2（COX-2）、血小板活化因子乙酰水解酶（PAF—AH）与血清超敏C反应蛋白（hsCRP）水平的变化及阿托伐他汀对它们的影响与意义。方法测定健康对照组（40例）、ACS组（45例）治疗前后外周血单个核细胞的COX-2、PAF—AH及hsCRP水平，并作比较。结果健康对照组COX-2（33．8±4．6）ng／ml]、PAF-AH（30．2±1．5）μmol·min^-1·L^-1]、hsCRP（1．1±0．8）g／L]，与ACS组治疗前COX-2（50．4±5．8）ng／ml]、PAF-AH（18．7±3．1）μmol·min^-1·L^-1]、hsCRP（19.3±5．6）g/L]差异有统计学意义（P〈0．05），ACS组治疗后COX-2（38．1±3．2）ng／ml]、PAF-AH（28．0±2．1）μmol·min^-1·L^-1]、hsCRP（7．4±1．8）g／L]与治疗前差异有统计学意义（P〈0．05）。结论炎性因子COX-2、PAF．AH、hsCRP与ACS的发病明显相关，阿托伐他汀可降低ACS患者的COX-2、hsCRP，升高PAF-AH，对减轻炎症反应、稳定斑块起着重要作用。

Effect of atorvastatin on cyclooxygenase-2 and platelet-activating factor acetylhydrolase and high sensitive C reactive protein in patients with acute coronary syndrome

Objective To study the level of cyclooxygenase-2 (COX-2) and platelet-activating factor acetyl-hydrolase(PAF-AH) and high sensitive C reactive protein(hsCRP) on peripheral blood mononuclear cells in Acute Coronary Syndrome(ACS) patients and the effect of atorvastatin on them and the clinical significance. Methods To measure and compare the content of COX-2,PAF-AH and hsCRP in normal control group and ACS group(before and after treatment). Result The content of COX-2,PAF-AH and hsCRP are significantly different between normal con-trol group and ACS group (before treatment) (P < 0.05), and between ACS group (before treatment) and ACS group (after treatment) too(P < 0.05). Conclusions The inflammatory cytokines COX-2,PAF-AH and haCRP have sig-nificant correlation with the occurance of ACS. Atorvastatin can decrease COX-2 and hsCRP level, and can increase PAF-AH level. So atorvastatin takes an important role in lessening inflamatory reaction level in ACS patients.